Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis

Recently, immune checkpoint inhibitors (ICIs) present promising application prospects in treating non-small cell lung cancer (NSCLC). This study aimed to investigate optimal treatment strategy by comparing the first-line treatment strategies with ICIs in NSCLC. We retrieved relevant studies on first...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yu, Zhang, Xiaoyan, Ning, Jiyu, Zhang, Manyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038046/
https://www.ncbi.nlm.nih.gov/pubmed/36715018
http://dx.doi.org/10.1080/21645515.2023.2169531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038046/
https://www.ncbi.nlm.nih.gov/pubmed/36715018
http://dx.doi.org/10.1080/21645515.2023.2169531

Ejemplares similares